The indications, cost, dose, side effects, pharmacokinetics, and drug interactions for soft-gel saquinavir and grepafloxacin are outlined. The bioavailability of soft-gel saquinavir (Fortovase) compared with the hard gel formulation (Invirase) is discussed. Grepafloxacin (Raxar), an oral fluoroquinolone from Glaxo-Wellcome, is active against nearly all strains of S. pneumoniae and will be potentially advantageous for pneumococcal pneumonia in HIV-infected patients. An analysis of Protocol M/333/0021, comparing AZT plus delavirdine (DLV) to AZT plus 3TC and AZT plus 3TC and DLV, is reviewed. A table lists the study results.
|Original language||English (US)|
|Number of pages||2|
|Journal||The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service|
|State||Published - Jan 1998|
ASJC Scopus subject areas